Trimspa (trimebutine maleate) coated tablets 200 mg. №30

Description

Trimspa (trimebutine maleate) coated tablets 200 mg. №30

Composition

active substance: trimebutine maleate;
1 tablet contains Trimebutin maleate 200 mg;
excipients: microcrystalline cellulose, lactose, tartaric acid, corn starch, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, hypromellose, diethyl phthalate, titanium dioxide (E 171), talc.

Dosage form

Film-coated tablets.

Basic physical and chemical properties: round biconvex tablets of white color, film-coated, smooth on both sides.

Pharmacological properties

Trimebutin is a synthetic agonist of peripheral opioid receptors m, d and k. The mechanism of action consists in direct action on the smooth muscles of the digestive tract and in the regulation of motor disorders without affecting the central nervous system. Unlike other opioids, trimebutin is not characterized by selectivity for one of the three types of receptors, due to which it can both enhance and suppress peristalsis. The process of normalization of motor skills begins 30 minutes after application of the drug.

Indications

Irritable bowel syndrome; functional disorders of the digestive tract, accompanied by abdominal pain, cramps, a feeling of fullness, flatulence, constipation or diarrhea.

Contraindication

Hypersensitivity to trimebutine or to other components of the drug Trimspa.

Use during pregnancy or lactation

Since there are no data on the use of the drug during pregnancy and lactation, it is contraindicated to prescribe to women during this period. Breastfeeding should be discontinued during treatment.
The ability to influence the reaction rate when driving vehicles or other mechanisms
In case of dizziness or drowsiness, you should refrain from driving or operating machinery.

Method of application and dosage

Take the Trimspa tablets orally, drink a glass of boiled water.

For adults, a single dose is 200 mg (1 tablet); daily dose – 600 mg (3 tablets).

At the beginning of the treatment of irritable bowel syndrome, the maximum daily dose for adults, if necessary, may be 600 mg (3 tablets), divided into 3 doses (ie 1 tablet 3 times a day).

The duration of therapy is determined by the doctor individually depending on the severity of the disease. Usually the course of treatment is 2-6 weeks, depending on the severity of the disease.

Children

Experience with the drug in children is limited, so it should not be prescribed to this category of patients.

Overdose

There are no data on cases of trimebutin overdose. Possible increased manifestations of adverse reactions.

Adverse reactions

• From the digestive tract: dry mouth, taste disturbance, diarrhea, dyspepsia, stomach pain, nausea, constipation;
• From the nervous system: drowsiness, fatigue, dizziness, anxiety, headache, feeling cold / warm, hearing impairment;
• From the immune system: allergic reactions, including skin rashes;
• Reproductive disorders: menstrual irregularities, painful breast enlargement;
• From the kidneys and urinary tract: urinary retention.